Results
1 -
10 of
18Renner et al..
Bioactivity-Guided Mapping and Navigation of Chemical Space, Nature Chemical Biology, 2009 A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity, Cancer Chemotherapy and Pharmacology Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice, Cancer Chemotherapy and Pharmacology Topoisomerase-I- und I/II- Hemmstoffe: die Zahl der Wirkstoffe und der therapeutischen M??glichkeiten w??chst, Der Onkologe Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies, Investigational New Drugs A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers, Investigational New Drugs Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors., Pharmacy World and Science Evolving lipid-based delivery systems in the management of neoplastic disease, Oncology Reviews Recent Advances in Camptothecin Drug Design and Delivery Strategies, Camptothecins in Cancer Therapy The Clinical Development of Lurtotecan, Camptothecins in Cancer Therapy